Market cap of Selecta Biosciences Inc. [SELB] reaches 165.29M – now what?


Selecta Biosciences Inc. [NASDAQ: SELB] gained 17.19% or 0.17 points to close at $1.17 with a heavy trading volume of 4393794 shares. The company report on May 17, 2022 that Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.

H.C. Wainwright Global Investment Conference Format: Pre-recorded presentation and one-on-one investor meetingsDate: Tuesday, May 24, 2022Time: Presentation available at 7:00 a.m. ETWebcast: Click Here.

It opened the trading session at $0.981, the shares rose to $1.26 and dropped to $0.9458, the range by which the price of stock traded the whole day. The daily chart for SELB points out that the company has recorded -60.47% loss over the past six months. However, it is still -80.0% lower than its most recent low trading price.

If we look at the average trading volume of 1.53M shares, SELB reached to a volume of 4393794 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Selecta Biosciences Inc. [SELB]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SELB shares is $7.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SELB stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

SVB Leerink have made an estimate for Selecta Biosciences Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 06, 2022. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on June 15, 2021, representing the official price target for Selecta Biosciences Inc. stock. Previously, the target price had yet another raise from $2.50 to $8, while Mizuho kept a Buy rating on SELB stock.

The Average True Range (ATR) for Selecta Biosciences Inc. is set at 0.12, with the Price to Sales ratio for SELB stock in the period of the last 12 months amounting to 1.53. The Price to Book ratio for the last quarter was 2.60, with the Price to Cash per share for the same quarter was set at 0.83.

Trading performance analysis for SELB stock

Selecta Biosciences Inc. [SELB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.62. With this latest performance, SELB shares gained by 36.00% in over the last four-week period, additionally sinking by -60.47% over the last 6 months – not to mention a drop of -75.16% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SELB stock in for the last two-week period is set at 68.38, with the RSI for the last a single of trading hit 77.99, and the three-weeks RSI is set at 60.21 for Selecta Biosciences Inc. [SELB]. The present Moving Average for the last 50 days of trading for this stock 0.9289, while it was recorded at 0.9427 for the last single week of trading, and 2.5997 for the last 200 days.

Selecta Biosciences Inc. [SELB]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Selecta Biosciences Inc. [SELB] shares currently have an operating margin of -5.40. Selecta Biosciences Inc.’s Net Margin is presently recorded at -30.19.

Return on Equity for this stock declined to -1,137.85, with Return on Assets sitting at -15.79.

Selecta Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.

An analysis of insider ownership at Selecta Biosciences Inc. [SELB]

There are presently around $57 million, or 36.80% of SELB stock, in the hands of institutional investors. The top three institutional holders of SELB stocks are: BLACKROCK INC. with ownership of 6,764,845, which is approximately -2.69% of the company’s market cap and around 5.90% of the total institutional ownership; VANGUARD GROUP INC, holding 5,690,224 shares of the stock with an approximate value of $5.68 million in SELB stocks shares; and ARTAL GROUP S.A., currently with $3.99 million in SELB stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Selecta Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 38 institutional holders increased their position in Selecta Biosciences Inc. [NASDAQ:SELB] by around 4,840,580 shares. Additionally, 60 investors decreased positions by around 6,277,946 shares, while 19 investors held positions by with 45,599,844 shares. The mentioned changes placed institutional holdings at 56,718,370 shares, according to the latest SEC report filing. SELB stock had 11 new institutional investments in for a total of 349,629 shares, while 18 institutional investors sold positions of 1,195,810 shares during the same period.